Published in Vaccine Weekly, June 16th, 2004
"Plasmodium falciparum kills 1-3 million people each year, most of them are children in sub-Saharan Africa. Immunization with a specific sequence of different vaccine carriers (prime boost) is particularly effective in conferring sterile protective immunity against the pre-erythrocytic stage in animal models of malaria. Here, we review the immunogenicity and protective efficacy data from the first human trial of a prime-boost vaccine against pre-erythrocytic malaria," scientists writing in the journal Trends in Parasitology report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.